)
Cellectar Biosciences (CLRB) investor relations material
Cellectar Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 progress centered on iopofosine I-131 for relapsed/refractory WM, with post-BTK inhibitor data supporting the planned accelerated-approval strategy.
Confirmatory Phase 3 preparation advanced, including site activation; a Phase 1b WM dosimetry study began, and CLR 125 development continued.
Financial highlights
Q3 2026 R&D expense was $5.44M vs. $2.5M in Q3 2025, reflecting Phase 3 preparation and increased CLR 125 trial activity.
Q3 2026 G&A expense was $2.67M vs. $2.3M in Q3 2025, primarily from higher professional fees and personnel costs.
Q3 operating expenses and operating loss were $8.10M vs. $4.85M; net loss was $7.97M vs. $4.44M, or $0.46 vs. $1.41/share.
9M 2026 operating expenses were $21.09M vs. $17.29M; net loss was $20.56M vs. $16.50M, or $1.81 vs. $7.82/share.
Outlook and guidance
First patient dosing in the randomized Phase 3 WM trial is targeted for Q1 2027; the trial plans ~100 patients per arm, with enrollment projected to take 18–24 months after first enrollment.
Accelerated NDA submission is targeted for H1 2027 and may occur at or after Phase 3 initiation; enrollment must be ongoing at the FDA decision. Full approval depends on superior PFS against a comparator.
Phase 1b WM dosimetry is expected to assess 20–30 newly diagnosed and relapsed patients; initial CLR 125 dosimetry and safety data were expected at a Q4 2026 medical meeting.
CLR 225 is Phase 1-ready, but trial initiation remains subject to corporate strategy.
- Iopofosine advances toward WM approval as the PDC pipeline expands into solid tumors.CLRB
Corporate presentation - Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials.CLRB
Corporate presentation - Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials.CLRB
Corporate presentation - Antigen-independent lipid raft targeting delivers diverse therapies with strong, durable efficacy.CLRB
Study update - Advanced clinical programs, strong efficacy, $34M cash, and 2027 NDA submission planned.CLRB
Q2 2026 - Lead radioconjugate shows robust efficacy in WM, with broad pipeline and strong financials.CLRB
Corporate presentation - Registering 51.9M shares for resale, company faces major regulatory and financial risks.CLRB
Registration filing - Shareholders will vote on governance, compensation, and capital-raising proposals, including major warrant exercises.CLRB
Proxy filing - Virtual Annual Meeting to vote on directors, stock plan, auditor, compensation, and warrants.CLRB
Proxy filing
Next Cellectar Biosciences earnings date
Next Cellectar Biosciences earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)